T-One Therapeutics Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$2.49M
- Investors
-
2
T-One Therapeutics General Information
Description
Operator of a healthcare company intended to offer anticancer therapies. The company deals with the development of new anticancer therapies and focuses on the regulation of the activation of T lymphocytes to some sequences of human DNA (LINE1), enabling medical professionals to access anticancer therapies to improve the treatment process.
Contact Information
Website
www.tonetx.euCorporate Office
- Via Francesco Sforza, 35
- 20122 Milan
- Italy
Corporate Office
- Via Francesco Sforza, 35
- 20122 Milan
- Italy
T-One Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC | 26-Sep-2022 | $2.49M | Completed | Generating Revenue | ||
| 1. University Spin-Out | 01-Jan-2022 | Completed | Generating Revenue |
T-One Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
T-One Therapeutics Patents
T-One Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026133224-A1 | A polynucleotide targeting line1 | Pending | 18-Dec-2024 | ||
| WO-2026133221-A1 | Immune cells with inhibited line1 expression | Pending | 18-Dec-2024 | ||
| AU-2021307106-A1 | Inhibitors of line1 and uses thereof | Pending | 17-Jul-2020 | ||
| CA-3189129-A1 | Inhibitors of line1 and uses thereof | Pending | 17-Jul-2020 | ||
| EP-3940075-A1 | Inhibitors of line1 and uses thereof | Inactive | 17-Jul-2020 | C12N15/113 |
T-One Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
T-One Therapeutics Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Utopia SIS | Venture Capital | Minority | ||
| National Institute of Molecular Genetics | University |
T-One Therapeutics FAQs
-
When was T-One Therapeutics founded?
T-One Therapeutics was founded in 2022.
-
Where is T-One Therapeutics headquartered?
T-One Therapeutics is headquartered in Milan, Italy.
-
What is the size of T-One Therapeutics?
T-One Therapeutics has 7 total employees.
-
What industry is T-One Therapeutics in?
T-One Therapeutics’s primary industry is Drug Discovery.
-
Is T-One Therapeutics a private or public company?
T-One Therapeutics is a Private company.
-
What is the current valuation of T-One Therapeutics?
The current valuation of T-One Therapeutics is .
-
What is T-One Therapeutics’s current revenue?
The current revenue for T-One Therapeutics is .
-
How much funding has T-One Therapeutics raised over time?
T-One Therapeutics has raised $2.49M.
-
Who are T-One Therapeutics’s investors?
Utopia SIS and National Institute of Molecular Genetics have invested in T-One Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
